As healthcare heats up on HKEX, Qiming sets up $500M fund dedicated to public companies
Since its founding in 2006, the partners at Qiming have built a rep for themselves as prescient venture investors, offering capital to startups like Zai Lab at a time when it was far from certain whether China’s nascent biopharma industry would ever take off.
But it did, and now Qiming has gathered $500 million to branch out.
The VC firm is now launching a public equities unit dubbed Springhill Fund, which will invest in listed companies in a variety of healthcare subsectors with an initial regional focus in Greater China and Asia, Endpoints News has learned.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.